Summary

The Global Patient-Derived Xenograft/PDX Model Market is valued at approximately USD 0.33 billion in 2024 and is projected to expand at a robust CAGR of 12.50% over the forecast period spanning 2025 to 2035, with historical data drawn from 2023 and 2024 and 2024 serving as the base year for estimation. Patient-Derived Xenograft models, which involve the implantation of human tumor tissues into immunodeficient animals, are increasingly being relied upon to replicate human cancer biology with high fidelity. These models have steadily worked their way into mainstream oncology research, enabling researchers to study tumor progression, drug response, and resistance mechanisms in a setting that closely mirrors clinical reality.
Market expansion is being powered by the accelerating pace of oncology drug discovery, the rising prevalence of cancer worldwide, and the pharmaceutical industryfs shift toward precision medicine. As conventional cell-line models fall short in predicting clinical outcomes, PDX models are increasingly being taken up as a more translationally relevant alternative. In parallel, advancements in implantation techniques, improved engraftment success rates, and growing collaborations between biotech firms, academic institutes, and contract research organizations are opening up new growth avenues. Despite these positives, the market continues to face headwinds related to high costs, extended timelines, and ethical considerations surrounding animal use, which may temper adoption across cost-sensitive research environments.

The detailed segments and sub-segments included in the report are:
By Type:
- Mouse
- Rat
By Service:
- Model Creation
- Characterization
By Implantation Method:
- Subcutaneous
By Tumor Type:
- Respiratory
- Gastrointestinal
- Gynecological
By Application:
- Preclinical
- Biomarker
By Region:
North America
- U.S.
- Canada
Europe
- UK
- Germany
- France
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
Middle East & Africa
- UAE
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Mouse-based PDX models are expected to dominate the Global Patient-Derived Xenograft/PDX Model Market over the forecast horizon, accounting for the largest share owing to their well-established biological compatibility, ease of handling, and extensive validation across oncology studies. Mouse models continue to be the preferred choice for preclinical cancer research due to their cost efficiency and wide availability of immunodeficient strains. While rat-based PDX models are gradually gaining attention for specific applications requiring larger sample volumes or complex surgical procedures, mouse models remain the industry standard and are anticipated to retain their leading position.
In terms of revenue contribution, model creation services currently lead the market, as pharmaceutical and biotechnology companies increasingly outsource complex and time-intensive PDX development workflows. Model creation commands a substantial share due to the technical expertise, infrastructure, and biological resources required to establish stable xenografts. Characterization services, however, are emerging as a fast-growing revenue stream, driven by the rising need for molecular profiling, biomarker validation, and pharmacodynamic assessments that enhance the predictive value of PDX platforms.
Geographically, North America dominates the Global Patient-Derived Xenograft/PDX Model Market, supported by a strong concentration of pharmaceutical and biotechnology companies, advanced research infrastructure, and significant funding for oncology research. Europe follows closely, benefiting from active academic research networks and increasing industry-academia collaborations. Asia Pacific is expected to register the fastest growth during the forecast period, as expanding clinical trial activity, growing biopharmaceutical investments, and improving research capabilities in countries such as China and Japan continue to push demand for advanced preclinical models.

Major market players included in this report are:
- Crown Bioscience Inc.
- Charles River Laboratories International, Inc.
- The Jackson Laboratory
- Envigo RMS LLC
- Champions Oncology, Inc.
- WuXi AppTec Co., Ltd.
- Taconic Biosciences, Inc.
- Pharmatest Services Ltd.
- Xentech SAS
- Oncodesign SA
- Hera BioLabs, Inc.
- Inotiv Inc.
- Sino-Biological Inc.
- Curia Global, Inc.
- Explora BioLabs

Global Patient-Derived Xenograft/PDX Model Market Report Scope:
- Historical Data - 2023, 2024
- Base Year for Estimation - 2024
- Forecast period - 2025-2035
- Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
- Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
- Customization Scope - Free report customization (equivalent to up to 8 analystsf working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments and countries in recent years and to forecast the values for the coming years, anchored firmly to 2024 while incorporating historical performance from 2023 and 2024. The report is designed to blend qualitative insights with quantitative rigor, offering a clear view of the drivers, challenges, and emerging opportunities shaping the marketfs future. It further delivers an in-depth evaluation of the competitive landscape, strategic initiatives, and service portfolios of key players operating across the global PDX model ecosystem.

Key Takeaways:
- Market Estimates & Forecast for 10 years from 2025 to 2035.
- Annualized revenues and regional-level analysis for each market segment.
- Detailed analysis of the geographical landscape with country-level analysis of major regions.
- Competitive landscape with information on major players in the market.
- Analysis of key business strategies and recommendations on future market approach.
- Analysis of the competitive structure of the market.
- Demand side and supply side analysis of the market.

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Global Patient-Derived Xenograft/PDX Model Market Report Scope & Methodology
1.1. Research Objective
1.2. Research Methodology
1.2.1. Forecast Model
1.2.2. Desk Research
1.2.3. Top Down and Bottom-Up Approach
1.3. Research Attributes
1.4. Scope of the Study
1.4.1. Market Definition
1.4.2. Market Segmentation
1.5. Research Assumption
1.5.1. Inclusion & Exclusion
1.5.2. Limitations
1.5.3. Years Considered for the Study

Chapter 2. Executive Summary
2.1. CEO/CXO Standpoint
2.2. Strategic Insights
2.3. ESG Analysis
2.4. key Findings

Chapter 3. Global Patient-Derived Xenograft/PDX Model Market Forces Analysis
3.1. Market Forces Shaping The Global Patient-Derived Xenograft/PDX Model Market (2025-2035)
3.2. Drivers
3.2.1. accelerating pace of oncology drug discovery
3.2.2. rising prevalence of cancer worldwide
3.3. Restraints
3.3.1. high costs, extended timelines, and ethical considerations
3.4. Opportunities
3.4.1. pharmaceutical industry’s shift toward precision medicine

Chapter 4. Global Patient-Derived Xenograft/PDX Model Industry Analysis
4.1. Porter’s 5 Forces Model
4.1.1. Bargaining Power of Buyer
4.1.2. Bargaining Power of Supplier
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Porter’s 5 Force Forecast Model (2025-2035)
4.3. PESTEL Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.3.5. Environmental
4.3.6. Legal
4.4. Top Investment Opportunities
4.5. Top Winning Strategies (2025)
4.6. Market Share Analysis (2025-2025)
4.7. Global Pricing Analysis And Trends 2025
4.8. Analyst Recommendation & Conclusion

Chapter 5. Global Patient-Derived Xenograft/PDX Model Market Size & Forecasts by Type 2025-2035
5.1. Market Overview
5.2. Global Patient-Derived Xenograft/PDX Model Market Performance - Potential Analysis (2025)
5.3. Mouse
5.3.1. Top Countries Breakdown Estimates & Forecasts, 2025-2035
5.3.2. Market size analysis, by region, 2025-2035
5.4. Rat
5.4.1. Top Countries Breakdown Estimates & Forecasts, 2025-2035
5.4.2. Market size analysis, by region, 2025-2035

Chapter 6. Global Patient-Derived Xenograft/PDX Model Market Size & Forecasts by Service 2025-2035
6.1. Market Overview
6.2. Global Patient-Derived Xenograft/PDX Model Market Performance - Potential Analysis (2025)
6.3. Model Creation
6.3.1. Top Countries Breakdown Estimates & Forecasts, 2025-2035
6.3.2. Market size analysis, by region, 2025-2035
6.4. Characterization
6.4.1. Top Countries Breakdown Estimates & Forecasts, 2025-2035
6.4.2. Market size analysis, by region, 2025-2035
Chapter 7. Global Patient-Derived Xenograft/PDX Model Market Size & Forecasts by Implantation Method 2025–2035
7.1. Market Overview
7.2. Global Patient-Derived Xenograft/PDX Model Market Performance - Potential Analysis (2025)
7.3. Subcutaneous
7.3.1. Top Countries Breakdown Estimates & Forecasts, 2025-2035
7.3.2. Market size analysis, by region, 2025-2035
Chapter 8. Global Patient-Derived Xenograft/PDX Model Market Size & Forecasts by Tumor type 2025–2035
8.1. Market Overview
8.2. Global Patient-Derived Xenograft/PDX Model Market Performance - Potential Analysis (2025)
8.3. Respiratory
8.3.1. Top Countries Breakdown Estimates & Forecasts, 2025-2035
8.3.2. Market size analysis, by region, 2025-2035
8.4. Gastrointestinal
8.4.1. Top Countries Breakdown Estimates & Forecasts, 2025-2035
8.4.2. Market size analysis, by region, 2025-2035
8.5. Gvnecological
8.5.1. Top Countries Breakdown Estimates & Forecasts, 2025-2035
8.5.2. Market size analysis, by region, 2025-2035
Chapter 9. Global Patient-Derived Xenograft/PDX Model Market Size & Forecasts by Application 2025–2035
9.1. Market Overview
9.2. Global Patient-Derived Xenograft/PDX Model Market Performance - Potential Analysis (2025)
9.3. Preclinical
9.3.1. Top Countries Breakdown Estimates & Forecasts, 2025-2035
9.3.2. Market size analysis, by region, 2025-2035
9.4. Biomarker
9.4.1. Top Countries Breakdown Estimates & Forecasts, 2025-2035
9.4.2. Market size analysis, by region, 2025-2035

Chapter 10. Global Patient-Derived Xenograft/PDX Model Market Size & Forecasts by Region 2025–2035
10.1. Growth Patient-Derived Xenograft/PDX Model Market, Regional Market Snapshot
10.2. Top Leading & Emerging Countries
10.3. North America Patient-Derived Xenograft/PDX Model Market
10.3.1. U.S. Patient-Derived Xenograft/PDX Model Market
10.3.1.1. Type breakdown size & forecasts, 2025-2035
10.3.1.2. Service breakdown size & forecasts, 2025-2035
10.3.1.3. Implantation Method breakdown size & forecasts, 2025-2035
10.3.1.4. Tumor Type breakdown size & forecasts, 2025-2035
10.3.1.5. Application breakdown size & forecasts, 2025-2035
10.3.2. Canada Patient-Derived Xenograft/PDX Model Market
10.3.2.1. Type breakdown size & forecasts, 2025-2035
10.3.2.2. Service breakdown size & forecasts, 2025-2035
10.3.2.3. Implantation Method breakdown size & forecasts, 2025-2035
10.3.2.4. Tumor Type breakdown size & forecasts, 2025-2035
10.3.2.5. Application breakdown size & forecasts, 2025-2035
10.4. Europe Patient-Derived Xenograft/PDX Model Market
10.4.1. UK Patient-Derived Xenograft/PDX Model Market
10.4.1.1. Type breakdown size & forecasts, 2025-2035
10.4.1.2. Service breakdown size & forecasts, 2025-2035
10.4.1.3. Implantation Method breakdown size & forecasts, 2025-2035
10.4.1.4. Tumor Type breakdown size & forecasts, 2025-2035
10.4.1.5. Application breakdown size & forecasts, 2025-2035
10.4.2. Germany Patient-Derived Xenograft/PDX Model Market
10.4.2.1. Type breakdown size & forecasts, 2025-2035
10.4.2.2. Service breakdown size & forecasts, 2025-2035
10.4.2.3. Implantation Method breakdown size & forecasts, 2025-2035
10.4.2.4. Tumor Type breakdown size & forecasts, 2025-2035
10.4.2.5. Application breakdown size & forecasts, 2025-2035
10.4.3. France Patient-Derived Xenograft/PDX Model Market
10.4.3.1. Type breakdown size & forecasts, 2025-2035
10.4.3.2. Service breakdown size & forecasts, 2025-2035
10.4.3.3. Implantation Method breakdown size & forecasts, 2025-2035
10.4.3.4. Tumor Type breakdown size & forecasts, 2025-2035
10.4.3.5. Application breakdown size & forecasts, 2025-2035
10.4.4. Spain Patient-Derived Xenograft/PDX Model Market
10.4.4.1. Type breakdown size & forecasts, 2025-2035
10.4.4.2. Service breakdown size & forecasts, 2025-2035
10.4.4.3. Implantation Method breakdown size & forecasts, 2025-2035
10.4.4.4. Tumor Type breakdown size & forecasts, 2025-2035
10.4.4.5. Application breakdown size & forecasts, 2025-2035
10.4.5. Italy Patient-Derived Xenograft/PDX Model Market
10.4.5.1. Type breakdown size & forecasts, 2025-2035
10.4.5.2. Service breakdown size & forecasts, 2025-2035
10.4.5.3. Implantation Method breakdown size & forecasts, 2025-2035
10.4.5.4. Tumor Type breakdown size & forecasts, 2025-2035
10.4.5.5. Application breakdown size & forecasts, 2025-2035
10.4.6. Rest of Europe Patient-Derived Xenograft/PDX Model Market
10.4.6.1. Type breakdown size & forecasts, 2025-2035
10.4.6.2. Service breakdown size & forecasts, 2025-2035
10.4.6.3. Implantation Method breakdown size & forecasts, 2025-2035
10.4.6.4. Tumor Type breakdown size & forecasts, 2025-2035
10.4.6.5. Application breakdown size & forecasts, 2025-2035
10.5. Asia Pacific Patient-Derived Xenograft/PDX Model Market
10.5.1. China Patient-Derived Xenograft/PDX Model Market
10.5.1.1. Type breakdown size & forecasts, 2025-2035
10.5.1.2. Service breakdown size & forecasts, 2025-2035
10.5.1.3. Implantation Method breakdown size & forecasts, 2025-2035
10.5.1.4. Tumor Type breakdown size & forecasts, 2025-2035
10.5.1.5. Application breakdown size & forecasts, 2025-2035
10.5.2. India Patient-Derived Xenograft/PDX Model Market
10.5.2.1. Type breakdown size & forecasts, 2025-2035
10.5.2.2. Service breakdown size & forecasts, 2025-2035
10.5.2.3. Implantation Method breakdown size & forecasts, 2025-2035
10.5.2.4. Tumor Type breakdown size & forecasts, 2025-2035
10.5.2.5. Application breakdown size & forecasts, 2025-2035
10.5.3. Japan Patient-Derived Xenograft/PDX Model Market
10.5.3.1. Type breakdown size & forecasts, 2025-2035
10.5.3.2. Service breakdown size & forecasts, 2025-2035
10.5.3.3. Implantation Method breakdown size & forecasts, 2025-2035
10.5.3.4. Tumor Type breakdown size & forecasts, 2025-2035
10.5.3.5. Application breakdown size & forecasts, 2025-2035
10.5.4. Australia Patient-Derived Xenograft/PDX Model Market
10.5.4.1. Type breakdown size & forecasts, 2025-2035
10.5.4.2. Service breakdown size & forecasts, 2025-2035
10.5.4.3. Implantation Method breakdown size & forecasts, 2025-2035
10.5.4.4. Tumor Type breakdown size & forecasts, 2025-2035
10.5.4.5. Application breakdown size & forecasts, 2025-2035
10.5.5. South Korea Patient-Derived Xenograft/PDX Model Market
10.5.5.1. Type breakdown size & forecasts, 2025-2035
10.5.5.2. Service breakdown size & forecasts, 2025-2035
10.5.5.3. Implantation Method breakdown size & forecasts, 2025-2035
10.5.5.4. Tumor Type breakdown size & forecasts, 2025-2035
10.5.5.5. Application breakdown size & forecasts, 2025-2035
10.5.6. Rest of APAC Patient-Derived Xenograft/PDX Model Market
10.5.6.1. Type breakdown size & forecasts, 2025-2035
10.5.6.2. Service breakdown size & forecasts, 2025-2035
10.5.6.3. Implantation Method breakdown size & forecasts, 2025-2035
10.5.6.4. Tumor Type breakdown size & forecasts, 2025-2035
10.5.6.5. Application breakdown size & forecasts, 2025-2035
10.6. Latin America Patient-Derived Xenograft/PDX Model Market
10.6.1. Brazil Patient-Derived Xenograft/PDX Model Market
10.6.1.1. Type breakdown size & forecasts, 2025-2035
10.6.1.2. Service breakdown size & forecasts, 2025-2035
10.6.1.3. Implantation Method breakdown size & forecasts, 2025-2035
10.6.1.4. Tumor Type breakdown size & forecasts, 2025-2035
10.6.1.5. Application breakdown size & forecasts, 2025-2035
10.6.2. Mexico Patient-Derived Xenograft/PDX Model Market
10.6.2.1. Type breakdown size & forecasts, 2025-2035
10.6.2.2. Service breakdown size & forecasts, 2025-2035
10.6.2.3. Implantation Method breakdown size & forecasts, 2025-2035
10.6.2.4. Tumor Type breakdown size & forecasts, 2025-2035
10.6.2.5. Application breakdown size & forecasts, 2025-2035
10.7. Middle East and Africa Patient-Derived Xenograft/PDX Model Market
10.7.1. UAE Patient-Derived Xenograft/PDX Model Market
10.7.1.1. Type breakdown size & forecasts, 2025-2035
10.7.1.2. Service breakdown size & forecasts, 2025-2035
10.7.1.3. Implantation Method breakdown size & forecasts, 2025-2035
10.7.1.4. Tumor Type breakdown size & forecasts, 2025-2035
10.7.1.5. Application breakdown size & forecasts, 2025-2035
10.7.2. Saudi Arabia (KSA) Patient-Derived Xenograft/PDX Model Market
10.7.2.1. Type breakdown size & forecasts, 2025-2035
10.7.2.2. Service breakdown size & forecasts, 2025-2035
10.7.2.3. Implantation Method breakdown size & forecasts, 2025-2035
10.7.2.4. Tumor Type breakdown size & forecasts, 2025-2035
10.7.2.5. Application breakdown size & forecasts, 2025-2035
10.7.3. South Africa Patient-Derived Xenograft/PDX Model Market
10.7.3.1. Type breakdown size & forecasts, 2025-2035
10.7.3.2. Service breakdown size & forecasts, 2025-2035
10.7.3.3. Implantation Method breakdown size & forecasts, 2025-2035
10.7.3.4. Tumor Type breakdown size & forecasts, 2025-2035
10.7.3.5. Application breakdown size & forecasts, 2025-2035

Chapter 11. Competitive Intelligence
11.1. Top Market Strategies
11.2. Crown Bioscience Inc.
11.2.1. Company Overview
11.2.2. Key Executives
11.2.3. Company Snapshot
11.2.4. Financial Performance (Subject to Data Availability)
11.2.5. Product/Services Port
11.2.6. Recent Development
11.2.7. Market Strategies
11.2.8. SWOT Analysis
11.3. Charles River Laboratories International, Inc.
11.4. The Jackson Laboratory
11.5. Envigo RMS LLC
11.6. Champions Oncology, Inc.
11.7. WuXi AppTec Co., Ltd.
11.8. Taconic Biosciences, Inc.
11.9. Pharmatest Services Ltd.
11.10. Xentech SAS
11.11. Oncodesign SA
11.12. Hera BioLabs, Inc.
11.13. Inotiv Inc.
11.14. Sino-Biological Inc.
11.15. Curia Global, Inc.
11.16. Explora BioLabs

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Patient-Derived Xenograft/PDX Model Market, Report Scope
Table 2. Global Patient-Derived Xenograft/PDX Model Market Estimates & Forecasts By Region 2025–2035
Table 3. Global Patient-Derived Xenograft/PDX Model Market Estimates & Forecasts By Segment 2025–2035
Table 4. Global Patient-Derived Xenograft/PDX Model Market Estimates & Forecasts By Segment 2025–2035
Table 5. Global Patient-Derived Xenograft/PDX Model Market Estimates & Forecasts By Segment 2025–2035
Table 6. Global Patient-Derived Xenograft/PDX Model Market Estimates & Forecasts By Segment 2025–2035
Table 7. Global Patient-Derived Xenograft/PDX Model Market Estimates & Forecasts By Segment 2025–2035
Table 8. U.S. Patient-Derived Xenograft/PDX Model Market Estimates & Forecasts, 2025–2035
Table 9. Canada Patient-Derived Xenograft/PDX Model Market Estimates & Forecasts, 2025–2035
Table 10. UK Patient-Derived Xenograft/PDX Model Market Estimates & Forecasts, 2025–2035
Table 11. Germany Patient-Derived Xenograft/PDX Model Market Estimates & Forecasts, 2025–2035
Table 12. France Patient-Derived Xenograft/PDX Model Market Estimates & Forecasts, 2025–2035
Table 13. Spain Patient-Derived Xenograft/PDX Model Market Estimates & Forecasts, 2025–2035
Table 14. Italy Patient-Derived Xenograft/PDX Model Market Estimates & Forecasts, 2025–2035
Table 15. Rest Of Europe Patient-Derived Xenograft/PDX Model Market Estimates & Forecasts, 2025–2035
Table 16. China Patient-Derived Xenograft/PDX Model Market Estimates & Forecasts, 2025–2035
Table 17. India Patient-Derived Xenograft/PDX Model Market Estimates & Forecasts, 2025–2035
Table 18. Japan Patient-Derived Xenograft/PDX Model Market Estimates & Forecasts, 2025–2035
Table 19. Australia Patient-Derived Xenograft/PDX Model Market Estimates & Forecasts, 2025–2035
Table 20. South Korea Patient-Derived Xenograft/PDX Model Market Estimates & Forecasts, 2025–2035
………….